Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

Jordi Remon; Lizza E.L. Hendriks

doi:10.1016/j.jtho.2020.11.027

Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

Jordi Remon, Lizza E.L. Hendriks

Résultats de recherche: Contribution à un journal › Editorial

7 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	368-370
Nombre de pages	3
journal	Journal of Thoracic Oncology
Volume	16
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.jtho.2020.11.027
état	Publié - 1 mars 2021
Modification externe	Oui

Accès au document

10.1016/j.jtho.2020.11.027

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{17209c2e5ba649f2aefa52d393743317,

title = "Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC",

author = "Jordi Remon and Hendriks, {Lizza E.L.}",

note = "Funding Information: Disclosure: Dr. Remon reports receiving other fees from Merck Sharp & Dohme, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, AstraZeneca, Roche, and personal and other fees from OSE Immunotherapeutics outside of the submitted work. Dr. Hendriks reports receiving other fees from Boehringer Ingelheim, Bristol-Myers Squibb, Roche Genentech, AstraZeneca, Eli Lilly, Pfizer, Merck Sharp & Dohme, Takeda, and Amgen; grants from Roche Genentech, Boehringer Ingelheim AstraZeneca; personal fees from Quadia; and nonfinancial support from AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, and Mirati outside of the submitted work. Funding Information: Disclosure: Dr. Remon reports receiving other fees from Merck Sharp & Dohme , Boehringer Ingelheim, Pfizer , Bristol-Myers Squibb , AstraZeneca , Roche , and personal and other fees from OSE Immunotherapeutics outside of the submitted work. Dr. Hendriks reports receiving other fees from Boehringer Ingelheim, Bristol-Myers Squibb , Roche Genentech, AstraZeneca , Eli Lilly , Pfizer , Merck Sharp & Dohme , Takeda, and Amgen ; grants from Roche Genentech, Boehringer Ingelheim AstraZeneca; personal fees from Quadia; and nonfinancial support from AstraZeneca , Novartis , Bristol-Myers Squibb , Merck Sharp & Dohme / Merck , GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, and Mirati outside of the submitted work. ",

year = "2021",

month = mar,

day = "1",

doi = "10.1016/j.jtho.2020.11.027",

language = "English",

volume = "16",

pages = "368--370",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "3",

}

TY - JOUR

T1 - Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC

AU - Remon, Jordi

AU - Hendriks, Lizza E.L.

N1 - Funding Information: Disclosure: Dr. Remon reports receiving other fees from Merck Sharp & Dohme, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, AstraZeneca, Roche, and personal and other fees from OSE Immunotherapeutics outside of the submitted work. Dr. Hendriks reports receiving other fees from Boehringer Ingelheim, Bristol-Myers Squibb, Roche Genentech, AstraZeneca, Eli Lilly, Pfizer, Merck Sharp & Dohme, Takeda, and Amgen; grants from Roche Genentech, Boehringer Ingelheim AstraZeneca; personal fees from Quadia; and nonfinancial support from AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, and Mirati outside of the submitted work. Funding Information: Disclosure: Dr. Remon reports receiving other fees from Merck Sharp & Dohme , Boehringer Ingelheim, Pfizer , Bristol-Myers Squibb , AstraZeneca , Roche , and personal and other fees from OSE Immunotherapeutics outside of the submitted work. Dr. Hendriks reports receiving other fees from Boehringer Ingelheim, Bristol-Myers Squibb , Roche Genentech, AstraZeneca , Eli Lilly , Pfizer , Merck Sharp & Dohme , Takeda, and Amgen ; grants from Roche Genentech, Boehringer Ingelheim AstraZeneca; personal fees from Quadia; and nonfinancial support from AstraZeneca , Novartis , Bristol-Myers Squibb , Merck Sharp & Dohme / Merck , GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, and Mirati outside of the submitted work.

PY - 2021/3/1

Y1 - 2021/3/1

UR - http://www.scopus.com/inward/record.url?scp=85101599700&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2020.11.027

DO - 10.1016/j.jtho.2020.11.027

M3 - Editorial

C2 - 33641720

AN - SCOPUS:85101599700

SN - 1556-0864

VL - 16

SP - 368

EP - 370

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 3

ER -